Strong preclinical immunization data for the ABNCoV2 cVLP-based COVID-19 vaccine published in Nature Communications
Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the publication of strong virus neutralization properties in animal proof-of-concept data for ABNCoV2, a unique capsid virus like particle (cVLP) based COVID-19 vaccine coated with ExpreS2-made SARS-CoV-2 antigens, in the esteemed scientific journal Nature Communications. The ABNCoV2 COVID-19 vaccine is the result of a strong collaboration effort by ExpreS2ion and its joint venture partner AdaptVac ApS (“AdaptVac”) together with the PREVENT-nCoV consortium, with an exclusive global